Tarsus Pharmaceuticals (TARS) Assets (2019 - 2026)

Tarsus Pharmaceuticals' Assets history runs 8 years deep, the most recent figure standing at $581.1 million for Q1 2026.

• On a quarterly basis, Assets rose 16.05% year-over-year to $581.1 million in Q1 2026; TTM through Mar 2026 was $581.1 million, a 16.05% increase from a year earlier, with the FY2025 full-year figure at $562.2 million, up 49.12% from the prior year.
• Assets grew to $581.1 million in Q1 2026 per TARS's latest filing, from $562.2 million in the prior quarter.
• Across five years, Assets topped out at $581.1 million in Q1 2026 and bottomed at $181.5 million in Q1 2022.
• The 5-year median for Assets is $349.3 million (2024), against an average of $352.1 million.
• Across the five-year window, Assets declined 25.27% in 2023 and surged 99.47% in 2024, its largest moves.
• Year by year, Assets stood at $227.9 million in 2022, then grew by 16.51% to $265.5 million in 2023, then surged by 42.0% to $377.0 million in 2024, then jumped by 49.12% to $562.2 million in 2025, then climbed by 3.38% to $581.1 million in 2026.
• Per Business Quant, the three latest TARS Assets figures stand at $581.1 million (Q1 2026), $562.2 million (Q4 2025), and $534.6 million (Q3 2025).